ZUMA-23: A phase 3 trial of axicabtagene ciloleucel in people with high-risk large B-cell lymphoma

This trial aims to test the medication axicabtagene ciloleucel as a first line treatment in people with high-risk large B-cell lymphoma.

You can share the following clinicaltrials.gov Identifier with your medical team so they can find out more about the trial: NCT05605899 

 

Trial aim and background 

The aim of this trial is to compare the treatment axicabtagene ciloleucel against the current standard-of-care treatment regimen in people with high-risk large B-cell lymphoma.

Participants in the trial will either receive axicabtagene ciloleucel and chemotherapy, or the current standard of care.

Who can enter

Adults with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) which is assessed to be high risk, and who have only received 1 cycle of rituximab and chemotherapy may be eligible for this trial.   

Locations

Recruitment is taking place at the following UK locations:

  • Addenbrookes Hospital, Birmingham
  • University Hospitals Southampton, Southampton

Further information

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/study/NCT05605899

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.